University of Berlin Charité, Department of Dermatology and Allergy
Welcome,         Profile    Billing    Logout  
 7 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Maurer, Marcus
RAPIDe-2, NCT05396105: Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema

Enrolling by invitation
2/3
140
Europe, Canada, US, RoW
deucrictibant selected dose, PHVS416, PHA121, PHA-022121
Pharvaris Netherlands B.V.
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema with C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency
06/27
06/27
HARBOR, NCT04910685 / 2020-005173-28: () Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Recruiting
2/3
463
Europe, US, RoW
Elenestinib, BLU-263, Placebo
Blueprint Medicines Corporation
Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, Smoldering Systemic Mastocytosis
06/28
06/28
RAPIDe-1, NCT04618211 / 2020-003445-11: Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

Completed
2
74
Europe, Canada, US, RoW
Deucrictibant, PHA-022121, PHA121, PHVS416, Placebo
Pharvaris Netherlands B.V.
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
09/22
03/23
CHED, NCT03749148 / 2017-001262-25: Cholinergic Urticaria - Efficacy of Dupilumab

Completed
2
48
Europe
Dupilumab, Placebo
Charite University, Berlin, Germany, Sanofi, Proinnovera GmbH
Cholinergic Urticaria
02/23
02/23
NCT05368285 / 2021-006413-11: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Active, not recruiting
2
208
Europe, US, RoW
barzolvolimab, CDX-0159, Matching Placebo
Celldex Therapeutics
Chronic Spontaneous Urticaria
09/23
03/25
CDX0159-07, NCT05405660 / 2021-006447-95: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Active, not recruiting
2
196
Europe, US, RoW
barzolvolimab, CDX-0159, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Chronic Inducible Urticaria
06/24
09/25
NCT01397864: C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

Recruiting
N/A
300
Europe, RoW
rhC1INH or pdC1INH, Ruconest
Pharming Technologies B.V.
Hereditary Angioedema
01/25
01/25
NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

No Longer Available
N/A
Europe, Canada, US
Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE), Angioedema
 
 
ENABLE, NCT04130191: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

Completed
N/A
140
Europe, RoW
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
09/24
09/24

Download Options